[LLY] Eli Lilly and Company $906.70
52-wk High $1133.95
📌 Investment Snapshot
- 💰 Price & Valuation: Trading at $906.70 with a P/E of 39.5x, a premium to the S&P 500 average.
- 📈 Latest Quarter: Q4 FY25 revenue hit $19.3B, a robust +42.6% YoY increase.
- 🔑 #1 Catalyst: Continued strong demand for its innovative diabetes and obesity drugs.
- 🎯 Consensus: BUY rating with a mean target of $1209, implying +33.3% upside.
| 📍 Entry Zone | $890.00 or below | 🛑 Stop-Loss | $840.00 |
| 📋 Adjust If | Q1 FY26 earnings miss revenue consensus by >5% or new clinical trial setback. | ||
The Investment Case — Why Now?
Eli Lilly is at a pivotal moment, with its stock currently trading at $906.70 after a recent pullback. The company reported a stellar Q4 FY25, with revenue surging +42.6% YoY to $19.3B, driven by the phenomenal success of its diabetes and weight-loss drugs, Mounjaro and Zepbound. This robust growth trajectory, coupled with an oversold RSI of 20.0 and the stock testing its 200-day SMA, presents a compelling entry point for investors looking for long-term growth in the pharmaceutical sector.
However, the primary risk lies in its elevated valuation, with a P/E of 39.5x, significantly higher than the S&P 500 average of 21.0x. This premium demands sustained, high-level performance and leaves little room for error. Any slowdown in drug adoption, increased competition, or unexpected regulatory hurdles could lead to a significant multiple contraction and downward pressure on the stock.
Company Overview
| Label | Value |
|---|---|
| Company | Eli Lilly and Company |
| Ticker / Exchange | LLY / NYSE |
| Sector / Industry | Healthcare / Drug Manufacturers – General |
| CEO | David Ricks |
| Founded / HQ | 1876 / Indianapolis, IN |
Peer P/E Comparison
| Ticker | Company | P/E (TTM) |
|---|---|---|
| LLY | (This stock) | 39.5x |
| S&P 500 Avg | S&P 500 Avg | 21.0x |
| UNH | UnitedHealth Group Incorporate | 21.2x |
| JNJ | Johnson & Johnson | 21.6x |
| PFE | Pfizer, Inc. | 20.1x |
| ABBV | AbbVie Inc. | 86.9x |
Price Action & Technicals
$906.70
-10.2%
-14.1%
-20.0%
LLY’s price action shows a recent downtrend, with the stock currently trading at $906.70, below its 50-day SMA ($1023.86) but finding potential support near its 200-day SMA ($890.21). The 14-day RSI of 20.0 signals that the stock is deeply oversold, suggesting a potential rebound. Furthermore, the price is positioned at the lower Bollinger Band, reinforcing the idea of an extreme move that could reverse.
Earnings Deep Dive
| Period | Revenue | EPS | YoY |
|---|---|---|---|
| Q4 FY25 | $19.3B | N/A | +42.6% |
| Q3 FY25 | $17.6B | $6.21 | +53.9% |
| Q2 FY25 | $15.6B | $6.29 | +37.6% |
| Q1 FY25 | $12.7B | $3.06 | +45.2% |
Growth Drivers — What Moves the Stock
- Blockbuster Drug Pipeline: Continued strong demand for diabetes and obesity drugs like Mounjaro and Zepbound is driving significant revenue growth and market share expansion. 🟢
- Global Market Expansion: Increasing penetration into international markets and new therapeutic areas is broadening its patient base and revenue streams, particularly in high-growth regions. 🟢
- R&D Innovation: Ongoing investment in research and development promises future breakthroughs and a robust pipeline of next-generation therapies, securing long-term growth. 🟡
Smart Money & Institutional Positioning
Top Institutional Holders (13F Filings)
| Institution | Shares (K) |
|---|---|
| Lilly Endowment, Inc | 92,190K |
| Vanguard Group Inc | 81,965K |
| Blackrock Inc. | 66,792K |
| PNC Financial Services G | 51,333K |
| State Street Corporation | 35,361K |
Holdings reflect most recent 13F (45-day lag). QoQ change not available.
Short Interest
| Short % of Float | Days to Cover |
|---|---|
| 0.85% | 1.9 |
Very low short interest — minimal bearish positioning, negligible squeeze potential.
Key Risk Factors — Risk Matrix
Regulatory Scrutiny & Pricing Pressure
Increased government and public pressure on drug pricing could lead to lower margins or restricted market access.
~$10B impact
Intense Competition
Emerging competitors in key therapeutic areas (e.g., GLP-1 agonists) could erode market share and pricing power.
~$12B impact
Clinical Trial Failures
High R&D costs and the inherent risk of late-stage clinical trial failures could impact future revenue streams.
~$15B impact
Supply Chain Disruptions
Reliance on complex global supply chains for manufacturing and distribution, vulnerable to geopolitical events.
~$5B impact
Guidance & Wall Street View
Recent Analyst Actions
| Firm | Rating | Price Target | Date | Action |
|---|---|---|---|---|
| HSBC | Reduce | $850.00 | 2026-03-17 | Downgrade |
| RBC Capital | Outperform | $1250.00 | 2026-02-25 | Initiate |
| Barclays | Overweight | $1350.00 | 2026-02-20 | Initiate |
| Deutsche Bank | Buy | $1285.00 | 2026-02-09 | Maintain |
| JP Morgan | Overweight | $1300.00 | 2026-02-05 | Maintain |
Analyst Consensus
| High Target | Mean Target | Low Target | Total Analysts | Consensus Rating |
|---|---|---|---|---|
| $1500 | $1209 | $850 | 29 | BUY |
The consensus ‘BUY‘ rating from 29 analysts, with a mean target of $1209, suggests a significant +33.3% upside from current levels, though the wide target range from $850 to $1500 indicates diverse views on future growth.
Bull vs Bear — Probability-Weighted Scenarios
Bull Case
- Continued blockbuster sales of Mounjaro and Zepbound, exceeding current analyst expectations and driving market share gains.
- Successful late-stage clinical trials and faster-than-anticipated regulatory approvals for new pipeline assets, broadening revenue streams.
Implied Price Target: $1350
Base Case
Eli Lilly maintains its strong growth trajectory, benefiting from its existing portfolio and a steady pipeline. Competition increases but is manageable, and regulatory environments remain stable. Valuation gradually normalizes towards a premium but not extreme multiple, reflecting its leadership position. Implied Fair Value: $1050.
Bear Case
- Significant clinical trial failures or unexpected safety concerns for key drugs, leading to pipeline delays or market withdrawal.
- Aggressive government intervention on drug pricing, coupled with intensified competition from generics or biosimilars, severely impacting margins.
Implied Price Target: $750
Disclaimer & Hashtags
This Veqtio analysis is for informational and educational purposes only and does not constitute investment advice. All investment decisions should be made based on your own research and due diligence. Past performance is not indicative of future results. Investing in securities involves risks, including the potential loss of principal.
All active positions and their real-time performance are tracked on our Investment Log.
#LLY #EliLilly #USStocks #StockAnalysis #Veqtio #Healthcare #Pharmaceuticals #Biotech